Drug-eluting stents for infrapopliteal arterial disease in the setting of critical limb ischemia

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 10, 2011, Pages 1339-1346

  Ward, Thomas J ^a   Lookstein, Robert A ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Cost; Drug eluting stents; Infrapopliteal; Peripheral artery disease

Indexed keywords

'TAXUS'; ACETYLSALICYLIC ACID; CLOPIDOGREL; CYPHER; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; RAPAMYCIN; UNCLASSIFIED DRUG; YUKON;

ANGIOGRAPHY; ANKLE BRACHIAL INDEX; ANTICOAGULANT THERAPY; ARTERY BLOOD FLOW; ARTERY BYPASS; ARTERY INTIMA PROLIFERATION; BAIL OUT DRUG ELUTING STENT; BARE METAL STENT; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CRITICAL LIMB ISCHEMIA; DEMOGRAPHY; DRUG ELUTING STENT; ENDOVASCULAR SURGERY; EPIDEMIOLOGICAL DATA; HEALTH CARE COST; HUMAN; IN-STENT RESTENOSIS; INFRAPOPLITEAL ARTERIAL DISEASE; LEG REVASCULARIZATION; LEG ULCER; LIMB ISCHEMIA; LIMB SALVAGE; MEDICARE; NEOINTIMA; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIMARY DRUG ELUTING STENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STENT THROMBOSIS; TARGET LESION REVASCULARIZATION; TREATMENT FAILURE; ULCER HEALING; VASCULAR PATENCY; WOUND HEALING;

DRUG-ELUTING STENTS; HUMANS; ISCHEMIA; LEG; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY;

EID: 80053944945     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.125     Document Type: Review

References (33)

1. Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119(3), e21-e181 (2009).
2. Rosamond W, Flegal K, Furie K et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117, e25-e146 (2008).
3. Ostchega Y, Paulose-Ram R, Dillon CF et al. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. J. Am. Geriatr. Soc. 55, 583-589 (2007). (Pubitemid 46496588)
4. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 349(9061), 1269-1276 (1997). (Pubitemid 27192468)
5. Heald CL, Fowkes FG, Murray GD et al. Ankle Brachial Index Collaboration. Risk of mortality and cardiovascular disease associated with the ankle-brachial index: systematic review. Atherosclerosis 189, 61-69 (2006). (Pubitemid 44441297)
6. Hirsch AT, Criqui MH, Treat-Jacobson D et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286, 1317-1324 (2001). (Pubitemid 33015522)
7. Norgren L, Hiatt WR, Dormandy JA et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J. Vasc. Surg. 45(Suppl. S), S5-S67 (2007). (Pubitemid 46151680)
8. Ouriel K, McDonnell AE, Metz CE, Zarins CK. Critical evaluation of stress testing in the diagnosis of peripheral vascular disease. Surgery 91, 686-693 (1982). (Pubitemid 13083950)
9. Wolfe JH, Wyatt MG. Critical and subcritical ischaemia. Eur. J. Vasc. Endovasc. Surg. 13, 578-582 (1997). (Pubitemid 27332193)
10. Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/ AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113(11), e463-e654 (2006).
11. Adam DJ, Beard JD, Cleveland T et al. Bypass Versus Angioplasty in Severe Ischaemia of the Leg (BASIL): multicentre, randomized controlled trial. Lancet 366(9501), 1925-1934 (2005). (Pubitemid 41713982)
12. Jaff M, Cahill K, Yu A, Birnbaum H, Engelhart L. Clinical outcomes and medical care costs among Medicare beneficiaries receiving therapy for peripheral arterial disease. Ann. Vasc. Surg. 24, 577-587 (2010).
13. Romiti M, Albers M, Brochado-Neto FC et al. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J. Vasc. Surg. 47, 975-981 (2008).
14. Vogel TR, Dombrovskiy VY, Carson JL, Graham AM. In-hospital and 30-day outcomes after tibioperoneal interventions in the US Medicare population with critical limb ischemia. J. Vasc. Surg. 54(1), 109-115 (2011).
15. Feiring AJ, Wesolowski AA, Lade S. Primary stent-supported angioplasty for treatment of below-knee critical limb ischemia and severe claudication: early and one-year outcomes. J. Am. Coll. Cardiol. 44, 2307-2314 (2004). (Pubitemid 39647603)
16. Aoki J, Colombo A, Dudek D et al. Persistent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: insights from serial intravascular ultrasound analysis in the TAXUS II study. Circulation 112(25), 3876-3883 (2005). (Pubitemid 43739485)
17. Grube E, Buellesfeld L. Paclitaxel eluting stents: current clinical experience. Am. J. Cardiovasc. Drugs 4(6), 355-360 (2004). (Pubitemid 39642488)
18. Stettler C, Wandel S, Allemann S et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370(9591), 937-948 (2007). (Pubitemid 47393576)
19. Rosales OR, Mathewkutty S, Gnaim C. Drug eluting stents for below the knee lesions in patients with critical limb ischemia: long-term follow-up. Catheter Cardiovasc. Interv. 72(1), 112-115 (2008). (Pubitemid 352008995)
20. Commeau P, Barragan P, Roquebert PO. Sirolimus for below the knee lesions: mid-term results of SiroBTK study. Catheter Cardiovasc. Interv. 68(5), 793-798 (2006). (Pubitemid 44721107)
21. Balzer JO, Zeller T, Rastan A et al. Percutaneous interventions below the knee in patients with critical limb ischemia using drug eluting stents. J. Cardiovasc. Surg. 51(2), 183-191 (2010).
22. Rastan A, Schwarzwalder U, Noory E et al. Primary use of sirolimus-eluting stents in the infrapopliteal arteries. J. Endovasc. Ther. 17, 480-487 (2010).
23. Siablis D, Karnabatidis D, Katsanos K et al. Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-term angiographic and clinical outcome. J. Vasc. Access 20(9), 1141-1150 (2009).
24. Scheinert D. Achilles study - randomized comparison of Sirolimus eluting stents vs PTA for BTK obstructions. Presented at: The Leipzig Interventional Course. Leipzig, Germany, 19 January 2011.
25. Zeller T. The Yukon BTK study - final results of the randomized, double blind study of DES vs BMS. Leipzig, Germany. Presented at: The Leipzig Interventional Course. Leipzig, Germany, 19 January 2011.
26. Bosiers M. DESTINY trial - 12 months clinical and angiographic findings. Presented at: The Leipzig Interventional Course. Leipzig, Germany, 19 January 2011.
27. Scheinert D, Ulrich M, Scheinert S et al. Comparison of sirolimus-eluting vs bare-metal stents for the treatment of infrapopliteal obstructions. Eurointervention 2(2), 169-174 (2006).
28. Scheinert D. Update: drug-eluting stents in tibial arteries. Endovasc. Today 8, 71-74 (2007).
29. Feiring AJ, Krahn M, Nelson L, Wesolowski A, Eastwood D, Szabo A. Preventing leg amputations in critical limb ischemia with below-the-knee drug-eluting stents: the PaRADISE (Preventing Amputations Using Drug Eluting Stents) trial. J. Am. Coll. Cardiol. 55(15), 1580-1589 (2010).
30. Karnabatidis D, Spiliopoulos S, Diamantopoulos A et al. Primary everolimus-eluting stenting versus balloon angioplasty with bailout bare metal stenting of long infrapopliteal lesions for treatment of critical limb ischemia. J. Endovasc. Ther. 18(1), 1-12 (2011).
31. Forbes JF, Adam DJ, Bell J et al. BASIL trial Participants. Bypass Versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: health-related quality of life outcomes, resource utilization, and cost-effectiveness analysis. J. Vasc. Surg. 51(5 Suppl.), S43-S51 (2010).
32. Filion KB, Roy AM, Baboushkin T, Rinfret S, Eisenberg MJ. Cost-effectiveness of drug-eluting stents including the economic impact of late stent thrombosis. Am. J. Cardiol. 103(3), 338-344 (2009
33. Katsanos K. Cost-effectiveness analysis of infrapopliteal drug-eluting stents for critical limb ischemia treatment. Presented at: Society of Interventional Radiology Annual Scientific Meeting. Chicago, IL, USA, 26-31 March 2011.